Chin ET, Leidner D, Ryckman T, Liu Y, Prince L, Alarid-Escudero F, Andrews JR, Salomon JA, Goldhaber-Fiebert JD, Studdert DM. Covid-19 Vaccine Acceptance in California State Prisons. New England Journal of Medicine, 2021;385(4):374-376.
Published in:
Abstract
To the Editor:
Prisons and jails are high-risk settings for Covid-19, with case and mortality rates far exceeding those in the general community.1 More incarcerated people have died from Covid-19 in U.S. correctional facilities in the past year than died by capital punishment in the past 70 years.2 Some states, including California, have prioritized incarcerated people for vaccination.
The California Department of Corrections and Rehabilitation (CDCR) provided anonymized data at the person-day level for all California prison residents from December 22, 2020, when the CDCR vaccination program began, through March 4, 2021. The data, which are described in the Supplementary Appendix (available with the full text of this letter at NEJM.org) and elsewhere,3 included variables that indicated which residents were offered doses of the BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine and which residents accepted. Our goal was to calculate the percentage of residents who accepted at least one dose among the residents who were offered doses and to use multivariable logistic regression analysis to estimate the probability of the acceptance of at least one dose according to the residents’ race or ethnic group, age group, medical vulnerability, and history of Covid-19. We also analyzed acceptance among residents who were reoffered vaccination after they had initially declined.
Two thirds of the 97,779 incarcerated residents were offered vaccines; among those offered a vaccine, 66.5% (42,952 of 64,633) accepted at least one dose. The results of adjusted analyses of the data for residents who were offered vaccination indicated that acceptance was highest among Hispanic residents (72.6%; 99.6% confidence interval [CI], 72.1 to 73.1) and White residents (72.1%; 99.6% CI, 71.3 to 72.9), slightly lower among American Indian or Alaska Native residents (67.7%; 99.6% CI, 64.4 to 71.0) and Asian or Pacific Islander residents (67.7%; 99.6% CI, 64.8 to 70.6), and substantially lower among Black residents (54.9%; 99.6% CI, 54.3 to 55.5) (Figure 1). Younger and healthier residents were less likely to accept vaccines than older and medically vulnerable residents. The percentages of residents who accepted did not differ appreciably according to residents’ history of Covid-19. Among the residents who had initially declined and were subsequently reoffered vaccination, 45.9% (901 of 1962) accepted at least one dose.
Most of the residents who were offered vaccines in the first 10 weeks of this program accepted, and the percentages of older and more medically vulnerable residents who accepted are similar to those reported in long-term care facilities.4 However, acceptance was markedly lower among residents at low risk for severe illness from Covid-19 and among non-Hispanic minorities, especially Black residents. Fewer than half of young, Black residents accepted at least one dose (Fig. S2), a finding that may reflect mistrust in correctional authorities and clinicians or a lack of access to reliable information on vaccine safety and efficacy.5 However, an encouraging finding was that a substantial proportion of residents who had initially declined a first dose later accepted a reoffer — an important indication that hesitancy is not necessarily fixed.
Even when Covid-19 vaccines become widely available in correctional institutions, achievement and maintenance of sufficient population-level immunity to avoid large outbreaks will be challenging. High and equitable vaccination uptake is crucial; attaining it may depend on successful efforts to build trust and vaccine confidence and on regular reoffers to those who decline initially.
Elizabeth T. Chin, B.S. Stanford University School of Medicine, Stanford, CA etchin@stanford.edu
David Leidner, Ph.D. San Luis Obispo, CA
Theresa Ryckman, B.A. Yiran E. Liu, B.S. Lea Prince, Ph.D. Stanford University School of Medicine, Stanford, CA
Fernando Alarid-Escudero, Ph.D. Center for Research and Teaching in Economics, Aguascalientes, Mexico
Jason R. Andrews, M.D. Joshua A. Salomon, Ph.D. Jeremy D. Goldhaber-Fiebert, Ph.D. David M. Studdert, LL.B., Sc.D. Stanford University School of Medicine, Stanford, CA